- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.03. | Psyence Biomedical Ltd.: Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone | 1 | GlobeNewswire (USA) | ||
| 03.03. | Psyence Biomedical Ltd.: Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial | 263 | GlobeNewswire (Europe) | NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| 02.03. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.02. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.02. | Psyence Biomedical Ltd.: Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment | 364 | GlobeNewswire (Europe) | NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| 17.02. | Psyence Biomedical Ltd.: Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders | 179 | GlobeNewswire (Europe) | NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 14.02. | Psyence Biomedical Ltd.: Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway | 410 | GlobeNewswire (Europe) | NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| 12.02. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 11.02. | Psyence Biomedical-Aktie fällt nach Beilegung von Aktionärsstreit | 1 | Investing.com Deutsch | ||
| 11.02. | Psyence Biomedical Ltd.: Psyence BioMed Announces Settlement of Shareholder Litigation | 385 | GlobeNewswire (Europe) | NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") today announced that it has entered into a settlement agreement to resolve a direct... ► Artikel lesen | |
| 03.02. | Morning Market Movers: FatPipe, FiEE, Teradyne, Psyence Biomedical, See Big Swings | 520 | AFX News | OTTAWA (dpa-AFX) - At 6:44 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 29.01. | Psyence Biomedical announces 1-for-6.25 share consolidation | 2 | Investing.com | ||
| 29.01. | Psyence Biomedical Ltd.: Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split | 113 | GlobeNewswire (Europe) | NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), today announced the effective date of its 1-for-6.25 share consolidation (reverse... ► Artikel lesen | |
| 27.01. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.01. | Psyence Biomedical Ltd.: Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026 | 2 | GlobeNewswire (USA) | ||
| 20.01. | Psyence Biomedical Ltd.: Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date | 188 | GlobeNewswire (Europe) | NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), today announced that it has decided to postpone the previously announced effective... ► Artikel lesen | |
| 15.01. | Psyence Biomedical sets Jan. 20 as effective date for reverse stock split | 1 | Seeking Alpha | ||
| 15.01. | Psyence Biomedical Ltd.: Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split | 249 | GlobeNewswire (Europe) | NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), today announced the effective date of its 1-for-6.25 share consolidation (reverse... ► Artikel lesen | |
| 15.01. | Psyence Biomedical announces 1-for-6.25 share consolidation | 1 | Investing.com | ||
| 08.01. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | - | SEC Filings |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOLINERX | 1,836 | +4,79 % | BioLineRx Ltd.: BioLineRx Reports 2025 Financial Results and Provides Corporate Update | - On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month -
- GLIX1 is positioned to potentially address... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 8,510 | -5,34 % | TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 | BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics... ► Artikel lesen | |
| MINK THERAPEUTICS | 7,500 | +2,04 % | MiNK Therapeutics, Inc. - 8-K, Current Report | ||
| SILEXION THERAPEUTICS | 1,340 | +5,51 % | Silexion Therapeutics Corp: Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer | Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 21,380 | +0,09 % | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| ADMA BIOLOGICS | 11,330 | -16,51 % | ADMA Biologics drops amid short report from Culper Research | ||
| QIAGEN | 34,465 | 0,00 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 30,640 | +2,82 % | Why Edgewise Therapeutics Stock Topped the Market on Tuesday | ||
| KINIKSA PHARMACEUTICALS | 44,940 | -2,33 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,570 | -3,05 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| ARCELLX | 114,66 | +0,05 % | Arcellx legt Zahlen vor - Augenmerk liegt auf Gilead-Übernahme | ||
| APOGEE THERAPEUTICS | 72,98 | -7,81 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 10,060 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 12,330 | -0,56 % | Stifel reiterates Buy on Contineum stock, keeps $29 price target | ||
| EVOTEC | 4,119 | 0,00 % | EQS-News: Evotec SE: Evotec erhält 10 Mio. $ Meilensteinzahlung von Bristol Myers Squibb im Rahmen der Protein-Degradation-Partnerschaft nach Start einer klinischen Studie | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec erhält 10 Mio. $ Meilensteinzahlung von Bristol Myers Squibb im Rahmen der Protein-Degradation-Partnerschaft nach Start einer... ► Artikel lesen |
PSYENCE BIOMEDICAL LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE BIOMEDICAL LTD finden Sie auf Wallstreet Online.